Denials and underpayment in drug-heavy practice
When a single claim can carry weeks of drug acquisition cost, the usual denial-management playbook is not enough. What changes.
7 min readGrowInfectiousDisease editorial
When a single claim can carry weeks of drug acquisition cost, the usual denial-management playbook is not enough. What changes.
7 min readGrowInfectiousDisease editorial

The short version
Standard denial management assumes claims are roughly comparable in value. In an infusion practice they are not, and that single fact changes how the function should be run.
A denial report sorted by count will put office-visit rejections at the top and a denied high-cost drug claim somewhere in the middle. Sorted by dollars, the ranking inverts entirely. Run both, and let the dollar ranking drive the work.
In a buy-and-bill model the drug was purchased before it was billed. A hard denial is therefore not deferred revenue — it is a realised loss on goods already consumed. Track hard-denial dollars separately and treat the figure as what it is: the direct cost of upstream process failure.
A drug claim paid at less than the contracted amount produces no rejection and no alert. Without loaded fee schedules the error is not rare — it is invisible. Given the value of individual drug claims, this is the highest-leverage single control an infusion practice can implement, and it is a systems configuration task rather than a labour one.
Monthly: hard-denial dollars by root cause, one category assigned to the process step that owns it, with a target and a date. Quarterly: a payment-variance review against contracted rates across your highest-value drug claims. That combination finds both the failures that shout and the ones that do not.
In drug-heavy ID work, prior authorization is not administrative overhead — it is the control that stands between a course of therapy and a written-off vial.
7 min readRead
Why a practice that dispenses expensive drugs is running a small pharmaceutical distribution business, and what that means for cash, risk and authorisation.
8 min readRead
When evaluation and management is the product, documentation is the product specification. The recurring places ID practices under-capture.
8 min readRead